Aug 15 (Reuters) - Pfizer Inc Chief Executive Officer Albert Bourla said on Monday he had tested positive for COVID-19 and was experiencing very mild symptoms.
Bourla said he had started a course of the company's oral COVID-19 antiviral treatment, Paxlovid, and was isolating and following all public health precautions.
Paxlovid is an antiviral medication that is used to treat high-risk patients, such as older people.
Bourla has received four doses of the COVID vaccine developed by Pfizer and its German partner BioNTech .
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments